Verici Dx plc (LON:VRCI – Get Free Report) fell 11.2% during trading on Wednesday . The stock traded as low as GBX 3.06 ($0.04) and last traded at GBX 3.22 ($0.04). 829,412 shares were traded during mid-day trading, an increase of 148% from the average session volume of 334,168 shares. The stock had previously closed at GBX 3.63 ($0.05).
Verici Dx Trading Down 14.2 %
The company has a 50 day moving average of GBX 6.38 and a 200 day moving average of GBX 7.02. The company has a debt-to-equity ratio of 4.65, a quick ratio of 8.49 and a current ratio of 4.54. The stock has a market capitalization of £7.54 million, a price-to-earnings ratio of -180.00 and a beta of 1.59.
About Verici Dx
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Recommended Stories
- Five stocks we like better than Verici Dx
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Ride Out The Recession With These Dividend Kings
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How to buy stock: A step-by-step guide for beginners
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
